In addition to CD180, chemokine receptor type 2 (CCR2) mRNA levels were downregulated in response to AZD5153 treatment, thus BRD4 inhibition may modulate the transmigration of tumor cells within the microenvironment (Macanas-Pirard et al. 2017). The gene discussed is CCR2; the disease is neoplasm.